Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec;78(12):3154-3165.
doi: 10.1111/all.15909. Epub 2023 Oct 4.

Blood CD62Llow inflammatory eosinophils are related to the severity of asthma and reduced by mepolizumab

Alessandra Vultaggio  1 , Matteo Accinno  1 , Emanuele Vivarelli  2 , Valentina Mecheri  1 , Giandomenico Maggiore  3 , Lorenzo Cosmi  1 , Paola Parronchi  1 , Olivero Rossi  4 , Enrico Maggi  5 , Oreste Gallo  3 , Andrea Matucci  4
Affiliations

Blood CD62Llow inflammatory eosinophils are related to the severity of asthma and reduced by mepolizumab

Alessandra Vultaggio et al. Allergy. 2023 Dec.

Abstract

Background: Eosinophils have been divided into different subpopulations with distinct phenotypes based on CD62L expression. No data are available regarding the correlation between eosinophils subphenotypes and clinical severity of asthma, as well as the effect of anti-IL-5 therapy on these cells. The study investigates the correlation between blood CD62Llow inflammatory eosinophils (iEos) and clinical severity of severe eosinophilic asthma (SEA) and evaluates the impact of mepolizumab on iEos.

Methods: 112 patients were screened and were divided in two groups: biological-naive (n = 51) and biological-treated patients (n = 61). The Biological-naive patients were analyzed before treatment (Group A) and 19 out of 51 patients, were longitudinally analyzed before and after treatment with mepolizumab 100 mg s.c/4 weeks (Group B); 32 patients were excluded because they were being treated with other biological therapies. Blood eosinophils were analyzed by FACS and correlated with clinical scores. In vitro effect of IL-5 and mepolizumab on CD62L expression was assessed.

Results: A significant correlation between blood CD62Llow cells and clinical scores of asthma and nasal polyps, as well as the number of asthma exacerbations in the last year was shown in untreated patients. In longitudinally studied patients we observed a marked reduction of CD62Llow cells paralleled by an increase in the proportion of CD62Lbright cells, associated with clinical improvement of asthma control. In vitro, CD62L expression on eosinophils is modulated by IL-5 and anti-IL-5.

Conclusion: A positive correlation between CD62Llow iEos and the baseline clinical features of SEA with CRSwNP was shown. Furthermore mepolizumab restores the healthy balance among eosinophils sub-phenotypes in SEA patients.

Keywords: CD62L; IL-5; eosinophils; inflammatory eosinophils; mepolizumab; nasal polyps; severe asthma.

PubMed Disclaimer

References

REFERENCES

    1. Robinson D, Humbert M, Buhl R, et al. Revisiting Type 2-high and Type 2-low airway inflammation in asthma: current knowledge and therapeutic implications. Clin Exp Allergy. 2017;47(2):161-175.
    1. Klion A. Recent advances in understanding eosinophil biology. F1000Res. 2017;6:1084.
    1. Simpson JL, Scott R, Boyle MJ, et al. Inflammatory subtypes in asthma: assessment and identification using induced sputum. Respirology. 2006;11(1):54-61.
    1. Foster PS, Mould AW, Yang M, et al. Elemental signals regulating eosinophil accumulation in the lung. Immunol Rev. 2001;179(1):173-181.
    1. Shaw DE, Sousa AR, Fowler SJ, et al. Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. Eur Respir J. 2015;46(5):1308-1321.

MeSH terms